AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
How to improve timing and duration of adjuvant chemotherapy
Authors: Colleoni, M Gelber, RD Gelber, S Castiglione-Gertsch, M Coates, AS Goldhirsch, A
Citation: M. Colleoni et al., How to improve timing and duration of adjuvant chemotherapy, BREAST, 10, 2001, pp. 101-105
Bone scan had no role in the staging of 765 consecutive operable T1-2N0-1 breast cancer patients without skeletal symptoms
Authors: Curigliano, G Ferretti, G Colleoni, M Marrocco, E Peruzzotti, G De Cicco, C Paganelli, G Goldhirsch, A
Citation: G. Curigliano et al., Bone scan had no role in the staging of 765 consecutive operable T1-2N0-1 breast cancer patients without skeletal symptoms, ANN ONCOL, 12(5), 2001, pp. 724-725
Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study
Authors: Nole, F Munzone, E Mandala, M Catania, C Orlando, L Zampino, MG Minchella, I Colleoni, M Peruzzotti, G Marrocco, E Goldhirsch, A
Citation: F. Nole et al., Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study, ANN ONCOL, 12(1), 2001, pp. 95-100
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
Authors: Colleoni, M Gelber, S Coates, AS Castiglione-Gertsch, M Gelber, RD Price, K Rudenstam, CM Lindtner, J Collins, J Thurlimann, B Holmberg, SB Cortes-Funes, H Simoncini, E Murray, E Fey, M Goldhirsch, A
Citation: M. Colleoni et al., Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer, J CL ONCOL, 19(21), 2001, pp. 4141-4149
Bone metastases in breast cancer: How to prevent? In reply
Authors: Colleoni, M Goldhirsch, A Coates, A Gelber, R Castiglione-Gertsch, M
Citation: M. Colleoni et al., Bone metastases in breast cancer: How to prevent? In reply, J CL ONCOL, 19(10), 2001, pp. 2764-2765
Nitroxide TEMPOL impairs mitochondrial function and induces apoptosis in HL60 cells
Authors: Monti, E Supino, R Colleoni, M Costa, B Ravizza, R Gariboldi, MB
Citation: E. Monti et al., Nitroxide TEMPOL impairs mitochondrial function and induces apoptosis in HL60 cells, J CELL BIOC, 82(2), 2001, pp. 271-276
Precipitated and spontaneous withdrawal in rats tolerant to anandamide
Authors: Costa, B Giagnoni, G Colleoni, M
Citation: B. Costa et al., Precipitated and spontaneous withdrawal in rats tolerant to anandamide, PSYCHOPHAR, 149(2), 2000, pp. 121-128
Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer
Authors: Ferretti, G Curigliano, G Pastorino, U Cittadini, A Flamini, G Calabro, MG De Pas, T Orlando, L Mandala, M Colleoni, M Spaggiari, L Granone, PL Pagliari, G de Braud, F Fazio, N Goldhirsch, A
Citation: G. Ferretti et al., Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer, CLIN CANC R, 6(6), 2000, pp. 2393-2400
Introducing taxanes in the adjuvant treatment of breast cancer: expectations and reality
Authors: Colleoni, M Orlando, L Nole, F Goldhirsch, A
Citation: M. Colleoni et al., Introducing taxanes in the adjuvant treatment of breast cancer: expectations and reality, BREAST, 9(3), 2000, pp. 134-138
Response to primary chemotherapy in breast cancer patients with tumors notexpressing estrogen and progesterone receptors
Authors: Colleoni, M Minchella, I Mazzarol, G Nole, F Peruzzotti, G Rocca, A Viale, G Orlando, L Ferretti, G Curigliano, G Veronesi, P Intra, M Goldhirsch, A
Citation: M. Colleoni et al., Response to primary chemotherapy in breast cancer patients with tumors notexpressing estrogen and progesterone receptors, ANN ONCOL, 11(8), 2000, pp. 1057-1059
Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required?
Authors: Orlando, L Colleoni, M Nole, F Biffi, R Rocca, A Curigliano, G Ferretti, G Peruzzotti, G de Braud, F Masci, G Goldhirsch, A
Citation: L. Orlando et al., Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): Is prophylaxis required?, ANN ONCOL, 11(1), 2000, pp. 117-118
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors
Authors: Colleoni, M Bonetti, M Coates, AS Castiglione-Gertsch, M Gelber, RD Price, K Rudenstam, CM Lindtner, J Collins, J Thurlimann, B Holmberg, S Veronesi, A Marini, G Goldhirsch, A
Citation: M. Colleoni et al., Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors, J CL ONCOL, 18(3), 2000, pp. 584-590
Identifying breast cancer patients at high risk for bone metastases
Authors: Colleoni, M O'Neill, A Goldhirsch, A Gelber, RD Bonetti, M Thurlimann, B Price, KN Castiglione-Gertsch, M Coates, AS Lindtner, J Collins, J Senn, HJ Cavalli, F Forbes, J Gudgeon, A Simoncini, E Cortes-Funes, H Veronesi, A Fey, M Rudenstam, CM
Citation: M. Colleoni et al., Identifying breast cancer patients at high risk for bone metastases, J CL ONCOL, 18(23), 2000, pp. 3925-3935
Intrapericardial treatment of neoplastic pericardial effusions
Authors: Martinoni, A Cipolla, CM Civelli, M Cardinale, D Lamantia, G Colleoni, M DeBraud, F Susini, G Martinelli, G Goldhirsh, A Fiorentini, C
Citation: A. Martinoni et al., Intrapericardial treatment of neoplastic pericardial effusions, HERZ, 25(8), 2000, pp. 787-793
Depression and degree of acceptance of adjuvant cytotoxic drugs
Authors: Colleoni, M Mandala, M Peruzzotti, G Robertson, C Bredart, A Goldhirsch, A
Citation: M. Colleoni et al., Depression and degree of acceptance of adjuvant cytotoxic drugs, LANCET, 356(9238), 2000, pp. 1326-1327
Loss of cannabinoid-stimulated guanosine 5 '-O-(3-[S-35]thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats
Authors: Rubino, T Vigano, D Costa, B Colleoni, M Parolaro, D
Citation: T. Rubino et al., Loss of cannabinoid-stimulated guanosine 5 '-O-(3-[S-35]thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats, J NEUROCHEM, 75(6), 2000, pp. 2478-2484
Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinol
Authors: Costa, B Colleoni, M
Citation: B. Costa et M. Colleoni, Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinol, EUR J PHARM, 395(1), 2000, pp. 1-7
Prediction of response to primary chemotherapy for operable breast cancer
Authors: Colleoni, M Orvieto, E Nole, F Orlando, L Minchella, I Viale, G Peruzzotti, G Robertson, C Noberasco, C Galimberti, V Sacchini, V Veronesi, P Zurrida, S Orecchia, R Goldhirsch, A
Citation: M. Colleoni et al., Prediction of response to primary chemotherapy for operable breast cancer, EUR J CANC, 35(4), 1999, pp. 574-579
Pre-operative chemotherapy and radiotherapy in breast cancer (vol 34, pg 641, 1998)
Authors: Colleoni, M Orecchia, R
Citation: M. Colleoni et R. Orecchia, Pre-operative chemotherapy and radiotherapy in breast cancer (vol 34, pg 641, 1998), EUR J CANC, 35(2), 1999, pp. 328-328
SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats
Authors: Costa, B Vailati, S Colleoni, M
Citation: B. Costa et al., SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats, BEHAV PHARM, 10(3), 1999, pp. 327-331
Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN)
Authors: Nole, F Minchella, I Colleoni, M Orvieto, E Munzone, E de Braud, F Peruzzotti, G Martinelli, G Zampino, MG Catania, C Pizzamiglio, M Veronesi, P Zurrida, S Galimberti, V Goldhirsch, A Veronesi, U
Citation: F. Nole et al., Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN), ANN ONCOL, 10(8), 1999, pp. 993-996
Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (cmf regimen)
Authors: Locatelli, M Colleoni, M Noberasco, C Nole, F Orlando, L Munzone, E Peruzzotti, G Goldhirsch, A
Citation: M. Locatelli et al., Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (cmf regimen), ANN ONCOL, 10(11), 1999, pp. 1394-1395
Pharmacokinetics of oral doxifluridine in patients with colorectal cancer
Authors: Zampino, MG Colleoni, M Bajetta, E Stampino, CG Guenzi, A de Braud, F
Citation: Mg. Zampino et al., Pharmacokinetics of oral doxifluridine in patients with colorectal cancer, TUMORI, 85(1), 1999, pp. 47-50
SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists
Authors: Costa, B Colleoni, M
Citation: B. Costa et M. Colleoni, SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists, ACT PHAR SI, 20(12), 1999, pp. 1103-1108
Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil
Authors: Colleoni, M Price, KN Castiglione-Gertsch, M Gelber, RD Coates, AS Goldhirsch, A
Citation: M. Colleoni et al., Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil, LANCET, 354(9173), 1999, pp. 130-131
Risultati: 1-25 | 26-27